Form D · Private Equity Fund

OrbiMed Royalty & Credit Opportunities III, LP

New York, NY · CIK 0001766289

Offering snapshot reported Jul 3, 2019 · SEC filing

Reported sold: $890M
Investors reported: 69
Minimum accepted: $0
First sale: Jan 30, 2019

What changed?

Latest filing versus its linked predecessor, where available.

Reported investors0 → 69

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 3, 2019	Amendment	$889,835,000	No comparison	69	SEC filing
Jan 29, 2019	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $0 (estimated)
Finders' fees: $0 (estimated)
Form D file number: 021-331673

Paid based on percentage of committed capital of investors introduced by selling agent. Management fees will be offset by any such amounts paid by the Issuer. Such amounts do not reduce the offering proceeds available for investment.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
J.P. Morgan Securities LLC	79

Source: Form D, filed Jul 3, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP

Investment adviser: ORBIMED ADVISORS LLC

Gross asset value: $359M
Beneficial owners: 113
ADV minimum commitment: $450K

Reported in Form ADV on Aug 18, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator SS&C TECHNOLOGIES, INC. NEW YORK, New York, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor KPMG LLP NEW YORK, New York, United States

Custodian JPMORGAN CHASE BANK, N.A. NEW YORK, New York, United States Related to adviser: No

Custodian SILICON VALLEY BANK NEWTON, Massachusetts, United States Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

KPMG LLP
PCAOB 185

Filing source

Form ADV 2126532 · Aug 18, 2026 · Schedule D 7.B.(1), fund 805-7281770620

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Sven H. Borho	Executive
Carl L. Gordon	Executive
Geoffrey C. Hsu	Executive
W. Carter Neild	Executive
N/A N/A Orbi Med Advisors Llc	Executive, Promoter
N/A N/A Orbi Med Rof Iii Llc	Executive
Jonathan T. Silverstein	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

601 Lexington Avenue 54 Th Floor
New York, NY, 10022